文献速递肝病

循环细胞外囊泡及其鞘脂货物用于酒精性肝炎诊断与动态风险分层

Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis.
PubMed 文献 · Hepatology · 2020-10-30

研究比较健康对照、重度饮酒者、终末期肝病、失代偿酒精性肝硬化及酒精性肝炎患者的血浆细胞外囊泡浓度与鞘脂货物。酒精性肝炎患者囊泡浓度显著更高且与MELD评分相关,高浓度组90天生存率低于低浓度组,囊泡鞘脂货物有诊断和预后价值。

要点

  • 血浆细胞外囊泡浓度在酒精性肝炎患者中显著升高,并与MELD评分相关。
  • 以中位数二分囊泡计数,高组90天生存率63.0%,低组90.0%(log-rank P=0.015)。
  • 囊泡鞘脂货物在酒精性肝炎中显著富集,多个鞘脂有良好诊断和预后性能。

核心结论

  • 循环细胞外囊泡浓度和鞘脂货物特征可用于酒精性肝炎的诊断、与其他病因终末期肝病及重度饮酒者的鉴别,并预测90天生存以进行动态风险分层。

研究设计与样本

  • 从健康对照、重度饮酒者、胆淤性肝病和非酒精性脂肪性肝炎所致终末期肝病、失代偿酒精性肝硬化及酒精性肝炎受试者血浆中分离并定量细胞外囊泡,并用串联质谱定量鞘脂。

主要发现

  • 酒精性肝炎患者血浆细胞外囊泡浓度中位数为5.38×10^11/mL,显著高于健康对照(4.38×10^10/mL,P<0.0001)、重度饮酒者(1.28×10^11/mL,P<0.0001)、终末期肝病(5.35×10^10/mL,P<0.0001)和失代偿酒精性肝硬化(9.2×10^10/mL,P<0.0001)。
  • 酒精性肝炎患者中细胞外囊泡浓度与MELD评分相关。
  • 以中位数二分囊泡计数,高囊泡组90天生存概率为63.0%,低囊泡组为90.0%(log-rank P=0.015)。
  • 与健康对照、重度饮酒者、终末期肝病和失代偿酒精性肝硬化相比,酒精性肝炎中细胞外囊泡鞘脂货物显著富集(P=0.0001)。
  • 多个鞘脂作为酒精性肝炎生物标志物表现出良好的诊断和预后性能。

临床怎么用

  • 可考虑检测血浆细胞外囊泡浓度及鞘脂货物,辅助酒精性肝炎的诊断、鉴别及90天生存风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Alcoholic hepatitis (AH) is diagnosed by clinical criteria, although several objective scores facilitate risk stratification. Extracellular vesicles (EVs) have emerged as biomarkers for many diseases and are also implicated in the pathogenesis of AH. Therefore, we investigated whether plasma EV concentration and sphingolipid cargo could serve as diagnostic biomarkers for AH and inform prognosis to permit dynamic risk profiling of AH subjects. APPROACH AND RESULTS: EVs were isolated and quantified from plasma samples from healthy controls, heavy drinkers, and subjects with end-stage liver disease (ESLD) attributed to cholestatic liver diseases and nonalcoholic steatohepatitis, decompensated alcohol-associated cirrhosis (AC), and AH. Sphingolipids were quantified by tandem mass spectroscopy. The median plasma EV concentration was significantly higher in AH subjects (5.38 × 1011 /mL) compared to healthy controls (4.38 × 1010 /mL; P < 0.0001), heavy drinkers (1.28 × 1011 /mL; P < 0.0001), ESLD (5.35 × 1010 /mL; P < 0.0001), and decompensated AC (9.2 × 1010 /mL; P < 0.0001) disease controls. Among AH subjects, EV concentration correlated with Model for End-Stage Liver Disease score. When EV counts were dichotomized at the median, survival probability for AH subjects at 90 days was 63.0% in the high-EV group and 90.0% in the low-EV group (log-rank P value = 0.015). Interestingly, EV sphingolipid cargo was significantly enriched in AH when compared to healthy controls, heavy drinkers, ESLD, and decompensated AC (P = 0.0001). Multiple sphingolipids demonstrated good diagnostic and prognostic performance as biomarkers for AH. CONCLUSIONS: Circulating EV concentration and sphingolipid cargo signature can be used in the diagnosis and differentiation of AH from heavy drinkers, decompensated AC, and other etiologies of ESLD and predict 90-day survival permitting dynamic risk profiling.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sehrawat TS, Arab JP, Liu M, et al. Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. Hepatology. 2020. PMID: 32246544. doi:10.1002/hep.31256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。